#USA #FDA Approval #Washington #Healthy Americas Foundation #Drug Trials

Disparities in Drug Trials: A Closer Look

The Healthy Americas Foundation recently released a significant report spotlighting the imbalance in drug trials conducted in the United States. Following an analysis of 46 novel medications approved by the FDA in 2025, it has become evident that the makeup of trial participants often does not reflect the actual demographic of patients who will ultimately use these drugs. In total, the study sampled around 26,000 participants, revealing a stark trend in clinical research that underscores the need for urgent reform.

Key Findings from the Report

1. International Participant Representation
A considerable number of trial participants were based outside the U.S. In various trials focusing on cancers and diseases affecting the heart, blood, and kidneys, a staggering 80% of participants were not from the United States. This discrepancy raises concerns about the relevance and applicability of the trial findings to the American population.

2. Underrepresentation of Ethnic Minorities
Another critical observation was the low enrollment of Black and Hispanic groups. In more than one-third of the trials that reported ethnic diversity, Hispanic participation accounted for a mere 5% or less. This lack of representation can lead to drugs that are ineffective or even harmful to minority populations, as the main demographics most affected by these diseases aren't adequately represented in the trials.

3. Neglect of Older Adults
Older adults aged 65 and over were also notably underrepresented, making up only a quarter to a third of participants in crucial trials for cancer and cardiovascular diseases. Given that these health issues predominantly affect older individuals, their absence in trials hinders the development of effective treatments for this demographic.

4. Specific Case Study: Multiple Myeloma
A glaring case highlighted in the report is that of a drug for multiple myeloma - a cancer that significantly affects Black Americans, with the incidence rate double that of White Americans. Alarmingly, only about 11 Black patients were enrolled in the trials for this medication.

The Path Forward: Practical Solutions

Despite these concerning findings, the report offers hope through practical and bipartisan solutions that can enhance trial representation. Some recommended actions include:

• - Setting enrollment goals based on disease prevalence and expected patient demographics.
• - Implementing minimum participation thresholds for specific demographics to ensure adequate representation.
• - Separating enrollment data by U.S. and non-U.S. participants to clarify the nuances in representation.
• - Reducing expenses associated with trial participation, such as travel and other out-of-pocket costs, which can dissuade potential participants from enrolling.

Dr. Jane L. Delgado, the President and CEO of the Healthy Americas Foundation, stated, “A pivotal trial has one job: to demonstrate whether a drug is effective and safe for those who will be using it. Too often in 2025, the evidence collected was based on populations that do not mirror those who will benefit from the drug. When the outcomes are not as anticipated, it’s the patients and their families who bear the consequences.”

Conclusion

This report shines a much-needed light on the persistent gaps in drug trials, advocating for a change that aligns trial participant demographics more closely with those living with the diseases. The necessary changes are achievable, as demonstrated by several successful trials in 2025 that effectively enrolled diverse patient groups. To view the complete report, visit Healthy Americas Foundation. By advocating for these changes, we can pave the way for more effective and safer treatments for everyone, regardless of their background or circumstances.